Title:
JAK INHIBITOR WITH HIGH ORAL BIOAVAILABILITY
Document Type and Number:
WIPO Patent Application WO/2023/011301
Kind Code:
A1
Abstract:
The present invention provides a JAK inhibitor having high oral bioavailability, characterized in that the JAK inhibitor comprises: a formula I compound, or a stereoisomer, geometric isomer, tautomer, hydrate, solvate, or pharmaceutically acceptable salt thereof as an active ingredient. The JAK inhibitor with high oral bioavailability provided by the present invention can overcome the problem that existing JAK inhibitors have low oral bioavailability, and involves further modifying a chemical compound so as to change the physicochemical characteristics of one or several small molecule compounds, thus increasing the in-vivo cell absorption performance of said compound(s), greatly improving the bioavailability of the medication and providing new possibilities for drug delivery and utilization for said compound medication.
Inventors:
FANG WENKUI (CN)
LI GUANQUN (CN)
CAI YUTING (CN)
PAN XIANG (CN)
ZHU WENHAO (CN)
WANG YANG (CN)
WANG ZENGQUAN (CN)
LI GUANQUN (CN)
CAI YUTING (CN)
PAN XIANG (CN)
ZHU WENHAO (CN)
WANG YANG (CN)
WANG ZENGQUAN (CN)
Application Number:
PCT/CN2022/108488
Publication Date:
February 09, 2023
Filing Date:
July 28, 2022
Export Citation:
Assignee:
TECHNODERMA MEDICINES INC (CN)
International Classes:
C07D401/14; A61K31/505; A61K31/506; A61P1/00; A61P11/00; A61P17/00; A61P17/06; A61P19/02; A61P19/08; A61P27/02; A61P29/00; A61P37/06; C07D239/42; C07D401/12
Foreign References:
| CN113603677A | 2021-11-05 | |||
| CN110627775A | 2019-12-31 | |||
| CN111961037A | 2020-11-20 | |||
| CN112142675A | 2020-12-29 | |||
| CN110734428A | 2020-01-31 | |||
| CN106928216A | 2017-07-07 |
Attorney, Agent or Firm:
ZHONG LUN LAW FIRM (CN)
Download PDF:
Previous Patent: METHOD AND APPARATUS FOR RECORDING FACIAL EXPRESSION OF VIDEO VIEWER
Next Patent: PHOTOGRAPHING METHOD AND RELATED APPARATUS
Next Patent: PHOTOGRAPHING METHOD AND RELATED APPARATUS